MX2009006319A - Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch. - Google Patents

Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch.

Info

Publication number
MX2009006319A
MX2009006319A MX2009006319A MX2009006319A MX2009006319A MX 2009006319 A MX2009006319 A MX 2009006319A MX 2009006319 A MX2009006319 A MX 2009006319A MX 2009006319 A MX2009006319 A MX 2009006319A MX 2009006319 A MX2009006319 A MX 2009006319A
Authority
MX
Mexico
Prior art keywords
haloalkyl
alkyl
phenyl
group
halo
Prior art date
Application number
MX2009006319A
Other languages
English (en)
Inventor
Kevin Matthew Gardinier
Erik James Hembre
David Joseph Garmene
Michael Brunavs
Helen Jane Szekeres
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39204735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009006319(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2009006319A publication Critical patent/MX2009006319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a un compuesto antagonista de hormona de concentración de melanina de la fórmula I, en donde '-----' está ausente o es opcionalmente un enlace; q es 1 ó 2; R1 independientemente se selecciona de hidrógeno, alquilo de C1-C2, halógeno, hidroxi, haloalquilo de C1-C2, ciano, -O-C3-C4 cicloalquilo, y -OC1-C2 haloalquilo; R2 se selecciona del grupo que consiste de hidrógeno, alquilo de C1-C3, hidroxi, alcoxi de C1-C3, ciano, haloalquilo de C1-C2, -OC1-C2 haloalquilo, y halógeno; R3 se selecciona del grupo que consiste de hidrógeno, alquilo de C1-C4, haloalquilo de C2-C4, alquilo de C2-C4-OH, cicloalquilo de C3-C6, -CH2C3-C6-cicloalquilo, alquilo de C2-C4-O-alquilo de C1-C4, -C(O)-alquilo de C1-C4, -CH2-tiazol, fenilo, bencilo, tetrahidrotiopiranilo, y tetrahidropiranilo, en donde el grupo cicloalquilo, tetrahidrotiopiranilo, tetrahidropiranilo y tiazolilo está opcionalmente substituido con uno o dos grupos independientemente seleccionados de del grupo que consiste de halógeno, hidroxi, alquilo de C1-C2 y haloalquilo de C1-C2; o una sal farmacéuticamente aceptable, enantiómero, diaestereómero, o mezcla de los mismos, útiles en el tratamiento, prevención o mejora de síntomas asociados con obesidad y enfermedades relacionadas.
MX2009006319A 2006-12-14 2007-11-15 Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch. MX2009006319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87001106P 2006-12-14 2006-12-14
PCT/US2007/084812 WO2008076562A1 (en) 2006-12-14 2007-11-15 5- [4- (azetidin-3-yl0xy) -phenyl] -2-phenyl-5h-thiaz0l0 [5,4-c] pyridin-4-0ne derivatives and their use as mch receptor antagonists

Publications (1)

Publication Number Publication Date
MX2009006319A true MX2009006319A (es) 2009-12-14

Family

ID=39204735

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006319A MX2009006319A (es) 2006-12-14 2007-11-15 Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch.

Country Status (16)

Country Link
US (1) US8049013B2 (es)
EP (1) EP2089397B1 (es)
JP (1) JP5269804B2 (es)
KR (1) KR20090082484A (es)
CN (1) CN101558075A (es)
AR (1) AR064127A1 (es)
AU (1) AU2007334171A1 (es)
BR (1) BRPI0721086A2 (es)
CA (1) CA2671765A1 (es)
CL (1) CL2007003480A1 (es)
EA (1) EA015559B1 (es)
ES (1) ES2392276T3 (es)
MX (1) MX2009006319A (es)
PE (1) PE20081572A1 (es)
TW (1) TW200831082A (es)
WO (1) WO2008076562A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
CN102666552B (zh) 2009-12-18 2014-11-26 詹森药业有限公司 作为mglur5受体的变构调节剂的双环噻唑
AU2010332819B2 (en) 2009-12-18 2014-02-27 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mGluR5 receptors
SG186275A1 (en) * 2010-07-06 2013-01-30 Astrazeneca Ab Therapeutic agents 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP6217653B2 (ja) * 2013-01-25 2017-10-25 セントラル硝子株式会社 α，α−ジフルオロアセトアルデヒドの製造方法
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
CN116082225A (zh) * 2016-08-08 2023-05-09 北京康蒂尼药业股份有限公司 一种羟尼酮的制备方法
CN116023327A (zh) * 2016-08-08 2023-04-28 北京康蒂尼药业股份有限公司 一种羟尼酮的制备方法
CN108997138A (zh) * 2018-08-17 2018-12-14 济南和润化工科技有限公司 一种无溶剂催化氢化法生产对氟苯胺的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
ATE446962T1 (de) * 2004-12-17 2009-11-15 Lilly Co Eli Thiazolopyridinon-derivate als mch- rezeptorantagonisten

Also Published As

Publication number Publication date
CL2007003480A1 (es) 2008-07-11
JP5269804B2 (ja) 2013-08-21
EP2089397B1 (en) 2012-08-29
WO2008076562A1 (en) 2008-06-26
ES2392276T3 (es) 2012-12-07
BRPI0721086A2 (pt) 2014-02-25
EP2089397A1 (en) 2009-08-19
AU2007334171A1 (en) 2008-06-26
EA200970582A1 (ru) 2010-02-26
EA015559B1 (ru) 2011-08-30
KR20090082484A (ko) 2009-07-30
AR064127A1 (es) 2009-03-11
US20100069352A1 (en) 2010-03-18
JP2010513292A (ja) 2010-04-30
CA2671765A1 (en) 2008-06-26
TW200831082A (en) 2008-08-01
CN101558075A (zh) 2009-10-14
PE20081572A1 (es) 2008-12-27
US8049013B2 (en) 2011-11-01

Similar Documents

Publication Publication Date Title
MX2009006319A (es) Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch.
MX2008016423A (es) Arilamidas sustituidas con tetrazol.
WO2010132580A3 (en) Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
WO2005080384A3 (en) Benzimidazole derivative and use as aii receptor antagonist
SI1828177T1 (sl) Novi antagonisti mch receptorja
TW200732313A (en) Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
TW200531694A (en) Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
MY148703A (en) Polycyclic cinnamide derivatives
MXPA05011670A (es) Derivados de azetidincarboxamida y su uso en el tratamiento de trastornos mediados por el receptor cb1.
MX2010002098A (es) Compuesto policiclico.
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
HK1138262A1 (en) Novel phosphodiesterase inhibitors
TW200716547A (en) Piperidin-4-yl-amide derivatives
RS51190B (sr) Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti
KR20090024811A (ko) 히스타민 ｈ3 수용체 조절제로서의 사이클로프로필 아민 유도체
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2007125398A3 (en) : sulfonamide compounds as antagonists of the n-type calcium channel
MX2010012421A (es) 5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1.
ATE399164T1 (de) Antagonisten des opioidrezeptors
CY1110950T1 (el) Ενωσεις ιμιδαζολιδινονυλ αμινοπυριμιδινης για τη θεραπευτικη αντιμετωπιση του καρκινου
MX2007006758A (es) Derivados de benzdioxanpiperazina con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina.
PL2139866T3 (pl) Krystaliczny 1-((2’-cyjanobifenylo-4-ylo)metylo)-2-etoksy-1H-benzo[d]imidazolo-7-karboksylan 1-(cykloheksyloksykarbonyloksy)etylu i sposób jego wytwarzania
EA015500B9 (ru) Новые антагонисты мсн рецепторов
PE20130781A1 (es) Agentes terapeuticos 976
WO2007000392A3 (en) Chloro-substituted guanidines

Legal Events

Date Code Title Description
FG Grant or registration